2023-01-24 11:00:00

InvestmentPitch Media Video Discusses Hemostemix and its Hiring of 4 Biotechnologists to Re-Establish Production of...

Logo GlobeNewswire

VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF) (FSE:2VF0), an autologous stem cell therapy company, is hiring four biotechnologists to re-establish the companys production of ACP-01 in Montreal. This staffing requirement arose because of the recently announced $250,000 Letter of Commitment for funding from the McGill University Health Centre Foundation to fund $250,000 of clinical trial expenses of a phase II double blind randomized clinical trial of ACP-01 as a treatment of ischemic cardiomyopathy at the McGill University Health Centre.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Hemostemix is hiring 4 Biotechnologists to Re-Establish Production of ACP-01 in Montreal, Following MUHC Foundation Funding and Applying for Grants to Fund Up to 75% of 5-Year Expenses: Hemostemix is hiring 4 Biotechnologists to Re-Establish Production of ACP-01 in Montreal, Following MUHC Foundation Funding and Applying for Grants to Fund Up to 75% of 5-Year Expenses

For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company, along with video comments from Thomas Smeenk, President and CEO of Hemostemix. The video is available for viewing on InvestmentPitch and on YouTube. If these links are not enabled, please visit www.InvestmentPitch.com and enter Hemostemix in the search box.

The company is hiring an experienced stem cell therapy Manufacturing Manager, a Quality Control Manager, and two Manufacturing Technologists.

Coincidentally, Hemostemix has applied for Federal and Provincial grant funding that may cover up to 75% of its capital and operating expenses to build and operate its cGMP facility during its first five years of operation.

Founded in 2003, Hemostemix principal business is to develop, manufacture and commercialize blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments. A winner of the World Economic Forum Technology Pioneer Award, the company is commercializing its lead product ACP-01, an autologous angiogenic cell precursor for cardiomyopathy and other diseases of ischemia. The companys process for harvesting stem cells is less invasive, as the stem cells are taken from a patients blood, which is a simplified process as compared to taking stem cells from fatty tissue or bone marrow.

The shares are currently trading at $0.25. For more information, please visit the companys website at www.hemostemix.com, contact Thomas Smeenk, President, CEO and Co-Founder at 905-580-4170 or by email at TSmeenk@hemostemix.com.

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a companys story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.


The information in this InvestmentPitch Media Ltd video is for the viewers information only. iMining has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format. The corporate information is based on information that is publicly available. Any information provided by InvestmentPitch Media Ltd., through its media services is not to be construed as a recommendation or suggestion or offer to buy or sell securities but is provided solely as an informational media service. InvestmentPitch Media Ltd makes no warranties or undertakings as to the accuracy or completeness of this information. All due diligence should be done by the viewer or their financial advisor. Investing in securities is speculative and carries risk.

InvestmentPitch Media
Barry Morgan, CFO

Continue read on globenewswire.com

Logo NewsFileCorp
Press Release2023-01-23 14:37:00
Calgary, Alberta--(Newsfile Corp. - January 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to...

Logo GlobeNewswire
SciencePress Release2023-01-23 11:00:00
VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF), an autologous stem cell therapy company, has...

Logo PR Newswire
HealthPress Release2023-01-24 10:56:00
Two successful exits – Syndesi and BioPhero Four portfolio companies reported clinical data from first in class targets (Galecto, NMD Pharma, Heparegenix and...

Logo NewsFileCorp
Press Release2023-01-19 16:28:00
Calgary, Alberta--(Newsfile Corp. - January 19, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it...

Logo NewsFileCorp
Press Release2023-01-23 14:09:00
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) (" GHG " or the " Company...

Logo PR Newswire
HealthPress Release2023-01-23 12:00:00
PRINCETON, N.J., Jan. 23, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 10:00:00
ATUM, a global specialist and industry leader in bioengineering solutions, today announced the signing of a full licensing agreement for the Leap-In...

Logo PR Newswire
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at...

Logo The Business Journals
Technology2023-01-23 19:47:07
Genetesis has added three new executives to its team as it nears a key FDA approval.

Logo GlobeNewswire
SciencePress Release2023-01-23 14:22:00
NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the Company or Bioasis ), a multi-asset rare and...

Logo GlobeNewswire
SciencePress Release2023-01-23 12:30:00
LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (iSpecimen or the Company), an online global marketplace that connects...

Logo EIN Presswire
HealthPress Release2023-01-23 13:38:17
Emergen Research Logo Increasing number of drug relapse and drug resistance cases and application of QSP in drug development processes are some key factors...

Logo Nasdaq
Business / FinanceBy Mt Newswires2023-01-23 14:13:11
Health care stocks were steady premarket Monday, with the Health Care Select Sector SPDR Fund ( XLV ) and the iShares Biotechnology ETF (IBB) unchanged....

Logo EIN Presswire
The Hemostats Market will be predicted to grow by 2028 with share, size, growth, and global demand and is expected to grow at an industry CAGR 6.3%. NEW...

Logo PR Newswire
TechnologyPress Release2023-01-23 13:00:00
– National Survey, Live Today, Will Benchmark Techquity in Healthcare Industry – NEW YORK, Jan. 23, 2023 /PRNewswire/ -- HLTH Foundation, a 501(c)3...

Logo GlobeNewswire
SciencePress Release2023-01-23 12:00:00
State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts Awarded $1.9 million of state and local grants with rent commencing in...

Logo GlobeNewswire
SciencePress Release2023-01-23 12:00:00
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the company has entered into a...

Logo GlobeNewswire
SciencePress Release2023-01-24 08:00:00
Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets LUGANO, Switzerland and...

Logo GlobeNewswire
SciencePress Release2023-01-23 13:03:00
CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical...